Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,621
archived clinical trials in
Urology

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Homewood, AL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Homewood, AL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aventura, FL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aventura, FL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orange City, FL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orange City, FL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Evanston, IL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Galesburg, IL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Galesburg, IL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Glenview, IL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Glenview, IL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Melrose Park, IL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Melrose Park, IL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Wayne, IN
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jeffersonville, IN
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New Orleans, LA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rockville, MD
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rockville, MD
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lansing, MI
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
LawrenceVille, NJ
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
LawrenceVille, NJ
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Albany, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Brooklyn, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Garden City, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Garden City, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Poughkeepsie, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Staten Island, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chapel Hill, NC
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lancaster, PA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lancaster, PA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Myrtle Beach, SC
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Arlington, TX
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sierra High Definition Ano-Rectal Manometry
Sierra High Definition Ano-Rectal Manometry
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Sierra High Definition Ano-Rectal Manometry
Sierra High Definition Ano-Rectal Manometry
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Chesapeake Urology
mi
from
Baltimore, MD
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Chesapeake Urology
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Urology Associates of Denver
mi
from
Englewood, CO
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Urology Associates of Denver
mi
from
Englewood, CO
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Sheldon J. Freedman, M.D., Ltd.
mi
from
Las Vegas, NV
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Sheldon J. Freedman, M.D., Ltd.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Scott and White Healthcare
mi
from
Temple, TX
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Scott and White Healthcare
mi
from
Temple, TX
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Genesis Research
mi
from
San Diego, CA
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Genesis Research
mi
from
San Diego, CA
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Shahram S. Gholami MD - A Professional Corp.
mi
from
San Jose, CA
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Shahram S. Gholami MD - A Professional Corp.
mi
from
San Jose, CA
Click here to add this to my saved trials